Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 679 across all filing types
Latest filing 2026-02-26 Earnings Release
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update
Earnings Release Classification · 100% confidence The document is a press release from GENFIT titled 'GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update'. It provides key financial highlights (cash position, revenue) and operational updates for the fourth quarter. Since it is an initial announcement of quarterly financial results containing key highlights rather than a full comprehensive interim report, it is classified as an Earnings Release (ER). Q4 2025
2026-02-26 English
GENFIT va recevoir un paiement d’étape de 20 M$ suite au dépassement du seuil des 200 M$ de ventes nettes d’Iqirvo® par Ipsen dès sa première année complète de commercialisation
Regulatory Filings Classification · 98% confidence The document is a press release from GENFIT announcing a milestone payment of $20 million triggered by the sales performance of Iqirvo, as well as updates on clinical trials and financial outlook. It is a corporate announcement regarding business operations and financial milestones, not a full financial report, transcript, or regulatory filing. It fits best under 'Regulatory Filings' (RNS) as a general corporate announcement of material information.
2026-02-12 French
GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales
Earnings Release Classification · 95% confidence The document is a press release from GENFIT announcing a US$20M milestone payment triggered by the commercial performance of their drug Iqirvo, as well as updates on clinical trials and future financial outlooks. It is a corporate announcement regarding business developments and financial events, which fits the definition of a Regulatory Filing (RNS) as it is a general corporate announcement that does not constitute a full financial report, earnings release, or other specific category. FY 2025
2026-02-12 English
Franchissement de seuil
Major Shareholding Notification Classification · 100% confidence The document is an official notice from the Autorité des marchés financiers (AMF) regarding a 'Déclaration de franchissement de seuil' (threshold crossing declaration). It details that 683 Capital Partners, LP has crossed the 5% threshold of voting rights in the company GENFIT. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2026-01-20 French
Franchissement de seuil
Major Shareholding Notification Classification · 100% confidence The document is an official notice from the Autorité des marchés financiers (AMF) regarding a 'Déclaration de franchissement de seuil' (threshold crossing declaration). It details that 683 Capital Partners, LP has crossed the 5% ownership threshold in the company GENFIT. This falls under the definition of a Major Shareholding Notification.
2026-01-19 French
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
Transaction in Own Shares Classification · 95% confidence The document is a press release from GENFIT detailing the semi-annual report of a liquidity contract with Crédit Industriel et Commercial. It provides specific transaction data (number of shares, amounts, and dates) for the second half of 2025. This type of disclosure regarding share buybacks and liquidity management falls under the category of 'Transaction in Own Shares' (POS).
2026-01-13 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.